Brandon Scalea

Danny Rischin, MD, discusses the potential of cemiplimab in patients with cervical cancer.

Fabrice Andre, MD, PhD, discusses the SOLAR-1 findings and their impact on the breast cancer landscape.

Scott T. Tagawa, MD, discusses an emerging treatment modality for patients with progressive metastatic castration-resistant prostate cancer.

Jonathon B. Cohen, MD, discusses the evolving landscape of mantle cell lymphoma.

Toni K. Choueiri, MD, discusses the JAVELIN Renal 101 study and where these data fit into the complex treatment paradigm of renal cell carcinoma.

Mark D. Pegram, MD, highlights the gradually evolving landscape of biosimilars and provides insight on how they can shape the US market.

Pembrolizumab (Keytruda) has emerged as an effective frontline treatment option for select patients with metastatic non–small cell lung cancer, showing an overall survival advantage across 3 phase III clinical trials.

The combination of dabrafenib and trametinib led to encouraging responses in patients with rare, incurable cancer of the digestive tract.

Simon Rule, MD, PhD, discusses the observational and active therapeutic approaches for patients with mantle cell lymphoma.

James Kearns, MD, discusses key issues to consider with surgery in patients with high-risk prostate cancer.

Roy S. Herbst, MD, PhD, discusses where future research is headed for immunotherapy in lung cancer.

D. Ross Camidge, MD, PhD, discusses the crowded landscape of oncogene-driven non­–small cell lung cancer.

Peter E. Clark, MD, discusses the role of surgery in the rapidly evolving treatment paradigm for patients with renal cell carcinoma.

Balazs Halmos, MD, MS, discusses overcoming acquired resistance and other next steps needed to advance the oncogene-driven non–small cell lung cancer paradigm.

Claud M. Grigg, Jr, MD, discusses the evolving treatment options in the frontline setting for patients with renal cell carcinoma.

Ronald de Wit, MD, PhD, discusses the clinical implications of pembrolizumab in the non–muscle invasive bladder cancer patient population.

Asim Amin, MD, discusses the current role of checkpoint inhibitors in advanced renal cell carcinoma and where the future is heading in this space.

Earle Burgess, MD, discusses the shifting paradigm of metastatic castration-sensitive prostate cancer.

Kashyap Patel, MD, discusses biosimilars and other potential cost-controlling measures in cancer care.

Missak Haigentz, MD, discusses the impact of EGFR TKIs on the treatment of patients with non–small cell lung cancer.

Neil P. Shah, MD, PhD, discusses emerging agents and the tyrosine kinase inhibitor discontinuation approach in the landscape of chronic myeloid leukemia.

Michelle E. Melisko, MD, discusses the clinical implications of the TAILORx and MINDACT studies.

Maurie Markman, MD, reflects on practice-changing advances during his career and discussed the future of gynecologic cancer treatment.

Lawrence D. Kaplan, MD, discusses recent updates and next steps in the expanding paradigm of Hodgkin lymphoma, mantle cell lymphoma, and follicular lymphoma.

Neil Morganstein, MD, discusses the intriguing PACIFIC results and the future role of immunotherapy in non–small cell lung cancer.

Brian T. Hill, MD, PhD, discusses recent advances and regulatory decisions in the treatment of patients with chronic lymphocytic leukemia.

Hossein Borghaei, DO, MS, discusses immunotherapy selection for the treatment of patients with non–small cell lung cancer.

Josep M. Llovet, MD, PhD, discusses the rapidly evolving treatment landscape for hepatocellular carcinoma and the work that lies ahead.

Ramsey N. Asmar, MD, discusses recent advances and next steps in small cell lung cancer.

Deborah A. Bradley, MD, discusses how recent clinical trials have impacted patients with nonmetastatic castration-resistant prostate cancer and what the future holds for them.